Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.
Sekeres MA, Tiu RV, Komrokji R, Lancet J, Advani AS, Afable M, Englehaupt R, Juersivich J, Cuthbertson D, Paleveda J, Tabarroki A, Visconte V, Makishima H, Jerez A, Paquette R, List AF, Maciejewski JP. Sekeres MA, et al. Among authors: tabarroki a. Blood. 2012 Dec 13;120(25):4945-51. doi: 10.1182/blood-2012-06-434639. Epub 2012 Aug 22. Blood. 2012. PMID: 22915641 Free PMC article. Clinical Trial.
Non-t(6;9) and Non-Inv(3) Balanced Chromosomal Rearrangements Are Associated With Poor Survival Outcomes in Myelodysplastic Syndromes.
Ai J, Visconte V, Tabarroki A, Hasrouni E, Hamilton BK, Mukherjee S, Kalaycio M, Sobecks R, Advani AS, Sekeres MA, Shetty S, Tiu RV. Ai J, et al. Among authors: tabarroki a. Clin Lymphoma Myeloma Leuk. 2015 Aug;15(8):489-95. doi: 10.1016/j.clml.2015.03.017. Epub 2015 Apr 2. Clin Lymphoma Myeloma Leuk. 2015. PMID: 25977195
Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms.
Traina F, Visconte V, Elson P, Tabarroki A, Jankowska AM, Hasrouni E, Sugimoto Y, Szpurka H, Makishima H, O'Keefe CL, Sekeres MA, Advani AS, Kalaycio M, Copelan EA, Saunthararajah Y, Olalla Saad ST, Maciejewski JP, Tiu RV. Traina F, et al. Among authors: tabarroki a. Leukemia. 2014 Jan;28(1):78-87. doi: 10.1038/leu.2013.269. Epub 2013 Sep 18. Leukemia. 2014. PMID: 24045501
Immunomodulatory agents in myelofibrosis.
Tabarroki A, Tiu RV. Tabarroki A, et al. Expert Opin Investig Drugs. 2012 Aug;21(8):1141-54. doi: 10.1517/13543784.2012.693913. Epub 2012 Jun 6. Expert Opin Investig Drugs. 2012. PMID: 22668122 Review.
Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy.
Mahfouz RZ, Jankowska A, Ebrahem Q, Gu X, Visconte V, Tabarroki A, Terse P, Covey J, Chan K, Ling Y, Engelke KJ, Sekeres MA, Tiu R, Maciejewski J, Radivoyevitch T, Saunthararajah Y. Mahfouz RZ, et al. Among authors: tabarroki a. Clin Cancer Res. 2013 Feb 15;19(4):938-48. doi: 10.1158/1078-0432.CCR-12-1722. Epub 2013 Jan 3. Clin Cancer Res. 2013. PMID: 23287564 Free PMC article.
Successful use of very low dose subcutaneous decitabine to treat high-risk myelofibrosis with Sweet syndrome that was refractory to 5-azacitidine.
Liu Y, Tabarroki A, Billings S, Visconte V, Rogers HJ, Hasrouni E, Englehaupt R, Kalaycio M, Sekeres MA, Saunthararajah Y, Tiu RV. Liu Y, et al. Among authors: tabarroki a. Leuk Lymphoma. 2014 Feb;55(2):447-9. doi: 10.3109/10428194.2013.802315. Epub 2013 Jun 24. Leuk Lymphoma. 2014. PMID: 23647061 No abstract available.
Splicing factor 3b subunit 1 (Sf3b1) haploinsufficient mice display features of low risk Myelodysplastic syndromes with ring sideroblasts.
Visconte V, Tabarroki A, Zhang L, Parker Y, Hasrouni E, Mahfouz R, Isono K, Koseki H, Sekeres MA, Saunthararajah Y, Barnard J, Lindner D, Rogers HJ, Tiu RV. Visconte V, et al. Among authors: tabarroki a. J Hematol Oncol. 2014 Dec 7;7:89. doi: 10.1186/s13045-014-0089-x. J Hematol Oncol. 2014. PMID: 25481243 Free PMC article.
Impact of allogeneic hematopoietic cell transplant in patients with myeloid neoplasms carrying spliceosomal mutations.
Hamilton BK, Visconte V, Jia X, Tabarroki A, Makishima H, Hasrouni E, Abounader D, Kalaycio M, Sekeres MA, Sobecks R, Duong Liu H, Bolwell B, Maciejewski JP, Copelan E, Tiu RV. Hamilton BK, et al. Among authors: tabarroki a. Am J Hematol. 2016 Jun;91(4):406-9. doi: 10.1002/ajh.24306. Epub 2016 Mar 14. Am J Hematol. 2016. PMID: 26799334 Free article.
A case of mistaken identity: When lupus masquerades as primary myelofibrosis.
Hasrouni E, Rogers HJ, Tabarroki A, Visconte V, Traina F, Afable M, Sekeres MA, Maciejewski JP, Tiu RV. Hasrouni E, et al. Among authors: tabarroki a. SAGE Open Med Case Rep. 2013 Aug 20;1:2050313X13498709. doi: 10.1177/2050313X13498709. eCollection 2013. SAGE Open Med Case Rep. 2013. PMID: 27489629 Free PMC article.
23 results